Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Patient online self-reporting of toxicity symptoms during chemotherapy.

Basch E, Artz D, Dulko D, Scher K, Sabbatini P, Hensley M, Mitra N, Speakman J, McCabe M, Schrag D.

J Clin Oncol. 2005 May 20;23(15):3552-61.

PMID:
15908666
2.

Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy.

Basch E, Iasonos A, Barz A, Culkin A, Kris MG, Artz D, Fearn P, Speakman J, Farquhar R, Scher HI, McCabe M, Schrag D.

J Clin Oncol. 2007 Dec 1;25(34):5374-80.

PMID:
18048818
3.

Feasibility of long-term patient self-reporting of toxicities from home via the Internet during routine chemotherapy.

Judson TJ, Bennett AV, Rogak LJ, Sit L, Barz A, Kris MG, Hudis CA, Scher HI, Sabattini P, Schrag D, Basch E.

J Clin Oncol. 2013 Jul 10;31(20):2580-5. doi: 10.1200/JCO.2012.47.6804. Epub 2013 Jun 3.

4.

Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial.

Basch E, Wood WA, Schrag D, Sima CS, Shaw M, Rogak LJ, Kris MG, Shouery M, Bennett A, Atkinson T, Pietanza MC.

Clin Trials. 2016 Jun;13(3):331-7. doi: 10.1177/1740774515615540. Epub 2015 Nov 4.

5.

Evaluation of an online platform for cancer patient self-reporting of chemotherapy toxicities.

Basch E, Artz D, Iasonos A, Speakman J, Shannon K, Lin K, Pun C, Yong H, Fearn P, Barz A, Scher HI, McCabe M, Schrag D.

J Am Med Inform Assoc. 2007 May-Jun;14(3):264-8. Epub 2007 Feb 28.

6.

Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials.

Basch E, Dueck AC, Rogak LJ, Minasian LM, Kelly WK, O'Mara AM, Denicoff AM, Seisler D, Atherton PJ, Paskett E, Carey L, Dickler M, Heist RS, Himelstein A, Rugo HS, Sikov WM, Socinski MA, Venook AP, Weckstein DJ, Lake DE, Biggs DD, Freedman RA, Kuzma C, Kirshner JJ, Schrag D.

JAMA Oncol. 2017 Aug 1;3(8):1043-1050. doi: 10.1001/jamaoncol.2016.6749.

PMID:
28208174
7.

Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes.

Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, Appawu M, Iasonos A, Atkinson T, Goldfarb S, Culkin A, Kris MG, Schrag D.

J Natl Cancer Inst. 2009 Dec 2;101(23):1624-32. doi: 10.1093/jnci/djp386. Epub 2009 Nov 17.

8.

Clinician versus nurse symptom reporting using the National Cancer Institute-Common Terminology Criteria for Adverse Events during chemotherapy: results of a comparison based on patient's self-reported questionnaire.

Cirillo M, Venturini M, Ciccarelli L, Coati F, Bortolami O, Verlato G.

Ann Oncol. 2009 Dec;20(12):1929-35. doi: 10.1093/annonc/mdp287. Epub 2009 Jul 17.

PMID:
19622510
9.

A prospective study of the feasibility and acceptability of a Web-based, electronic patient-reported outcome system in assessing patient recovery after major gynecologic cancer surgery.

Andikyan V, Rezk Y, Einstein MH, Gualtiere G, Leitao MM Jr, Sonoda Y, Abu-Rustum NR, Barakat RR, Basch EM, Chi DS.

Gynecol Oncol. 2012 Nov;127(2):273-7. doi: 10.1016/j.ygyno.2012.07.124. Epub 2012 Aug 4.

10.
11.

Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study.

Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris MG, Scher HI, Schrag D.

Lancet Oncol. 2006 Nov;7(11):903-9.

PMID:
17081915
12.

Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial.

Basch E, Pugh SL, Dueck AC, Mitchell SA, Berk L, Fogh S, Rogak LJ, Gatewood M, Reeve BB, Mendoza TR, O'Mara AM, Denicoff AM, Minasian LM, Bennett AV, Setser A, Schrag D, Roof K, Moore JK, Gergel T, Stephans K, Rimner A, DeNittis A, Bruner DW.

Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):409-418. doi: 10.1016/j.ijrobp.2017.02.002. Epub 2017 Feb 10.

PMID:
28463161
13.

Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials.

Basch E, Rogak LJ, Dueck AC.

Clin Ther. 2016 Apr;38(4):821-30. doi: 10.1016/j.clinthera.2016.03.011. Epub 2016 Apr 2.

14.

Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials.

Di Maio M, Gallo C, Leighl NB, Piccirillo MC, Daniele G, Nuzzo F, Gridelli C, Gebbia V, Ciardiello F, De Placido S, Ceribelli A, Favaretto AG, de Matteis A, Feld R, Butts C, Bryce J, Signoriello S, Morabito A, Rocco G, Perrone F.

J Clin Oncol. 2015 Mar 10;33(8):910-5. doi: 10.1200/JCO.2014.57.9334. Epub 2015 Jan 26.

15.

Gynecologic oncology patients' satisfaction and symptom severity during palliative chemotherapy.

von Gruenigen VE, Hutchins JR, Reidy AM, Gibbons HE, Daly BJ, Eldermire EM, Fusco NL.

Health Qual Life Outcomes. 2006 Oct 30;4:84.

16.

Health-related quality of life in early breast cancer.

Groenvold M.

Dan Med Bull. 2010 Sep;57(9):B4184.

PMID:
20816024
17.

Application of mobile phone technology for managing chemotherapy-associated side-effects.

Weaver A, Young AM, Rowntree J, Townsend N, Pearson S, Smith J, Gibson O, Cobern W, Larsen M, Tarassenko L.

Ann Oncol. 2007 Nov;18(11):1887-92. Epub 2007 Oct 5.

PMID:
17921245
18.

Stakeholder perspectives on implementing the National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Bruner DW, Hanisch LJ, Reeve BB, Trotti AM, Schrag D, Sit L, Mendoza TR, Minasian L, O'Mara A, Denicoff AM, Rowland JH, Montello M, Geoghegan C, Abernethy AP, Clauser SB, Castro K, Mitchell SA, Burke L, Trentacosti AM, Basch EM.

Transl Behav Med. 2011 Mar;1(1):110-22. doi: 10.1007/s13142-011-0025-3.

19.

Self-evaluation of Adjuvant Chemotherapy-Related Adverse Effects by Patients With Breast Cancer.

Montemurro F, Mittica G, Cagnazzo C, Longo V, Berchialla P, Solinas G, Culotta P, Martinello R, Foresto M, Gallizioli S, Calori A, Grasso B, Volpone C, Bertola G, Parola G, Tealdi G, Giuliano PL, Aglietta M, Ballari AM.

JAMA Oncol. 2016 Apr;2(4):445-52. doi: 10.1001/jamaoncol.2015.4720.

20.

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.

Forbes C, Shirran L, Bagnall AM, Duffy S, ter Riet G.

Health Technol Assess. 2001;5(28):1-110. Review.

Supplemental Content

Support Center